WT1 mutations in T-ALL

Blood

Volumn 114, Issue 5, 2009, Pages 1038-1045

  Tosello, Valeria ^a   Mansour, Marc R ^b   Barnes, Kelly ^a   Paganin, Maddalena ^c   Sulis, Maria Luisa ^a,d   Jenkinson, Sarah ^b   Allen, Christopher G ^b   Gale, Rosemary E ^b   Linch, David C ^b   Palomero, Teresa ^a,d   Real, Pedro ^a,e   Murty, Vundavalli ^a   Yao, Xiaopan ^f   Richards, Susan M ^g   Goldstone, Anthony ^h   Rowe, Jacob ⁱ   Basso, Giuseppe ^c   Wiernik, Peter H ^j,k   Paietta, Elisabeth ^j,k   Pieters, Rob ^l,m   Horstmann, Martin ^n,o   Meijerink, Jules P P ^l   Ferrando, Adolfo A ^a,d   more..

^a Columbia University ^*  (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF PADOVA   (Italy)

^d Department of Medicine   (United States)

^e Centro de Investigacion Biomedica   (Spain)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

^h UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

ⁱ TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^j MONTEFIORE MEDICAL CENTER   (United States)

^k NEW YORK MEDICAL COLLEGE   (United States)

^l SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^m DCOG Dutch Childhood Oncology Group   (Netherlands)

ⁿ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^o German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia (COALL)   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HOXA; TRANSCRIPTION FACTOR TLX1; TRANSCRIPTION FACTOR TLX3; UNCLASSIFIED DRUG; WT1 PROTEIN; DNA; TUMOR PROTEIN; ZINC FINGER PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHILD; CHROMOSOME DELETION; CONTROLLED STUDY; DISEASE COURSE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MUTATION RATE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM; CELL CLONE; CHEMISTRY; CHROMOSOME ABERRATION; DNA METHYLATION; GENETICS; HOMEOBOX; KAPLAN MEIER METHOD; MORTALITY; MUTATION; ONCOGENE; TUMOR SUPPRESSOR GENE;

ADULT; CHILD; CHROMOSOME ABERRATIONS; CLONE CELLS; DISEASE PROGRESSION; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GENES, HOMEOBOX; GENES, WILMS TUMOR; HUMANS; KAPLAN-MEIERS ESTIMATE; MUTATION; NEOPLASM PROTEINS; ONCOGENES; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECURRENCE; WT1 PROTEINS; ZINC FINGERS;

EID: 70349232830     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-12-192039     Document Type: Article

References (49)

1. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350(15): 1535-1548.
2. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030-1043.
3. Bickmore WA, Porteous DJ, Christie S, et al. CpG islands surround a D segment located between translocation breakpoints associated with genitourinary dysplasia and aniridia. Genomics. 1989; 5(4):685-693.
4. Habib R, Loirat C, Gubler MC, et al. The nephropathy associated with male pseudohermaphroditism and Wilm's' tumor (Drash syndrome): a distinctive glomerular lesion - report of 10 cases. Clin Nephrol. 1985;24(6):269-278. (Pubitemid 16186426)
5. Haber DA, Buckler AJ, Glaser T, et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilm's' tumor. Cell. 1990;61(7):1257-1269. (Pubitemid 20208830)
6. Carapeti M, Goldman JM, Cross NC. Dominant-negative mutations of the Wilm's' tumour predisposing gene (WT1) are infrequent in CML blast crisis and de novo acute leukaemia. Eur J Haematol. 1997;58(5):346-349. (Pubitemid 27286667)
7. King-Underwood L, Pritchard-Jones K. Wilm's' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood. 1998;91(8):2961-2968. (Pubitemid 28227547)
8. King-Underwood L, Renshaw J, Pritchard-Jones K. Mutations in the Wilm's' tumor gene WT1 in leukemias. Blood. 1996;87(6):2171-2179. (Pubitemid 26086855)
9. Van Vlierberghe P, Homminga I, Zuurbier L, et al. Cooperative genetic defects in TLX3 rearranged pediatric T-ALL. Leukemia. 2008;22(4):762-770. (Pubitemid 351552625)
10. Palomero T, Barnes KC, Real PJ, et al. CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors. Leukemia. 2006;20(7):1279-1287. (Pubitemid 43905832)
11. Li C, Hung Wong W. Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol. 2001;2(8):RESEARCH0032.
12. WengAP, Ferrando AA, LeeW, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306(5694):269-271. (Pubitemid 39336870)
13. Mansour MR, Duke V, Foroni L, et al. Notch-1 mutations are secondary events in some patients with T-cell acute lymphoblastic leukemia. Clin Cancer Res. 2007;13(23):6964-6969. (Pubitemid 350276876)
14. Thompson BJ, Buonamici S, Sulis ML, et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med. 2007; 204(8):1825-1835. (Pubitemid 47236320)
15. van Grotel M, Meijerink JP, Beverloo HB, et al. The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols. Haematologica. 2006;91(9):1212-1221.
16. van Grotel M, Meijerink JP, van Wering ER, et al. Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia. 2008;22(1):124-131.
17. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 1997;25(12):2532-2534. (Pubitemid 27303718)
18. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758-764. (Pubitemid 46582031)
19. Kuiper RP, Schoenmakers EF, van Reijmersdal SV, et al. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia. 2007;21(6):1258-1266.
20. Paulsson K, Cazier JB, Macdougall F, et al. Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: unexpected similarities with pediatric disease. Proc Natl Acad Sci U S A. 2008;105(18):6708-6713. (Pubitemid 351754571)
21. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 2008;8(2):83-93. (Pubitemid 351161321)
22. Graux C, Cools J, Melotte C, et al. Fusion of NUP214 toABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet. 2004;36(10):1084- 1089. (Pubitemid 41184470)
23. Menke A, McInnes L, Hastie ND, Schedl A. The Wilm's' tumor suppressor WT1: approaches to gene function. Kidney Int. 1998;53(6):1512-1518. (Pubitemid 28243735)
24. Little M, Wells C. A clinical overview of WT1 gene mutations. Hum Mutat. 1997;9(3):209-225. (Pubitemid 27138814)
25. Akasaka Y, Kikuchi H, Nagai T, Hiraoka N, Kato S, Hata J. A point mutation found in the WT1 gene in a sporadic Wilm's' tumor without genito-urinary abnormalities is identical with the most frequent point mutation in Denys-Drash syndrome. FEBS Lett. 1993;317(1-2):39-43. (Pubitemid 23043935)
26. Little MH, Williamson KA, Mannens M, et al. Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a dominant-negative fashion. Hum Mol Genet. 1993;2(3):259-264. (Pubitemid 23129085)
27. Sulis ML, Williams O, Palomero T, et al. NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood. 2008;112(3):733-740.
28. O'Neil J, Grim J, Strack P, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med. 2007;204(8):1813-1824. (Pubitemid 47236319)
29. Akhoondi S, Sun D, von der Lehr N, et al. FBXW7/ hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 2007;67(19):9006-9012. (Pubitemid 47535882)
30. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1(1):75-87. (Pubitemid 41039178)
31. Bernard OA, Busson-LeConiat M, Ballerini P, et al. A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia. Leukemia. 2001;15(10):1495-1504. (Pubitemid 32994666)
32. Soulier J, Clappier E, Cayuela JM, et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (TALL). Blood. 2005;106(1):274-286. (Pubitemid 40967203)
33. Van Vlierberghe P, van Grotel M, Tchinda J, et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood. 2008;111(9):4668-4680.
34. Virappane P, Gale R, Hills R, et al. Mutation of the Wilm's' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2008; 26(33):5429-5435.
35. Paschka P, Marcucci G, Ruppert AS, et al. Wilm's' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2008;26(28):4595-4602.
36. Vieira Pinheiro JP, Wenner K, Escherich G, et al. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97. Pediatr Blood Cancer. 2006;46(1):18-25. (Pubitemid 41779313)
37. Ferrando AA, Look AT. Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia. Semin Hematol. 2000;37(4):381-395. (Pubitemid 30796697)
38. Aifantis I, Raetz E, Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol. 2008;8(5):380-390. (Pubitemid 351595220)
39. O'Neil J, Look AT. Mechanisms of transcription factor deregulation in lymphoid cell transformation. Oncogene. 2007;26(47):6838-6849. (Pubitemid 47585107)
40. Clappier E, Cuccuini W, Kalota A, et al. The CMYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. Blood. 2007;110(4):1251-1261. (Pubitemid 47281423)
41. Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991;66(4):649-661. (Pubitemid 121001701)
42. Lahortiga I, De Keersmaecker K, Van Vlierberghe P, et al. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet. 2007; 39(5):593-595. (Pubitemid 46676109)
43. O'Neil J, Tchinda J, Gutierrez A, et al. Alu elements mediate MYB gene tandem duplication in human T-ALL. J Exp Med. 2007;204(13):3059-3066.
44. Gump J, McGavran L, Wei Q, Hunger SP. Analysis of TP53 mutations in relapsed childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2001;23(7):416-419. (Pubitemid 33031768)
45. Hsiao MH, Yu AL, Yeargin J, Ku D, Haas M. Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase. Blood. 1994;83(10):2922-2930. (Pubitemid 24142725)
46. Haber DA, Timmers HT, Pelletier J, Sharp PA, Housman DE.Adominant mutation in the Wilm's tumor gene WT1 cooperates with the viral oncogene E1Ain transformation of primary kidney cells. Proc Natl Acad Sci U S A. 1992;89(13):6010-6014.
47. Little M, Holmes G, Bickmore W, van Heyningen V, Hastie N, Wainwright B. DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations. Hum Mol Genet. 1995;4(3):351-358.
48. Summers K, Stevens J, Kakkas I, et al. Wilm's' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia. 2007;21(3):550-551; author reply 552. (Pubitemid 46306568)
49. Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science. 2008; 322(5906):1377-1380. (Pubitemid 352775249)